Last reviewed · How we verify
NCT07511127
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
Phase 3 trial testing Maribavir in Hematologic Malignancy in 218 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 218 |
| Start date | 28 February 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Maribavir (MARIBAVIR) — full drug profile →
Conditions studied
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
Sponsor
Ruijin Hospital
Who can join
Adults 18 to 75, any sex, with Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07511127
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Maribavir
Trials testing the same drug.
- NCT07014319 — Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies · Phase 2 · recruiting
- NCT06439342 — A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections · Phase 3 · recruiting
- NCT06577363 — A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection · recruiting
- NCT05319353 — A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment · Phase 3 · recruiting
- NCT06034925 — Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients · Phase 4 · completed
Other recruiting trials for Hematologic Malignancy
Currently open trials in the same condition.
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT07035938 — T-cell Developmental Status in Patients With Malignant Hematological Tumors · recruiting
- NCT06989489 — Implementation of an Oral Chemotherapy Adherence Intervention · NA · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07511127 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07511127.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing